1.Research progress on Ecoflex in the field of stomatology
BI Huimin ; CHEN Jianhang ; ZHANG Jingxin ; YANG Maohua ; DENG Shuangshan ; SU Yingyue ; GAO Shanshan
Journal of Prevention and Treatment for Stomatological Diseases 2026;34(5):507-517
Ecoflex is a commercial designation for elastomers developed based on the principles of environmental sustainability and flexibility. Various manufacturers offer different types of Ecoflex products with distinct compositions and functions. Among these, the platinum-catalyzed silicone rubber Ecoflex series has demonstrated considerable applicability in various fields of oral medicine due to its excellent flexibility, biocompatibility, stability across a wide temperature range, and tunable mechanical properties. In tissue engineering, it can simulate the mechanical behavior of oral mucosa, and is used in cleft lip surgical training models and preoperative evaluation for temporal bone defect reconstruction. In the field of wearable devices, leveraging its encapsulation protection and flexible characteristics, highly sensitive sensors constructed from Ecoflex can monitor signals such as oral bite force and masticatory muscle activity, thereby aiding in the diagnosis of temporomandibular joint disorders and postoperative evaluation of cleft lip and palate. Moreover, when combined with bio-waste materials, it promotes the functionalization and sustainability of oral wearable devices.In drug delivery systems, its conformability and controlled-release capability address challenges in localized oral drug administration. Designs such as flexible microneedles and temperature-responsive composite systems provide precise solutions for treating periodontitis and oral ulcers. In minimally invasive surgical instruments, its softness enables the development of soft robots and magnetically controlled microfluidic valves, enhancing surgical safety and precision. In the field of oral rehabilitation, Ecoflex soft liner materials, inspired by the suction cup structure of octopus tentacles, improve denture retention. Their low modulus reduces mucosal irritation, ensuring both comfort and durability. Although Ecoflex shows great potential in biomedical applications, it still faces certain challenges, particularly regarding long-term stability after implantation, mechanical fatigue resistance, and microbial colonization, which require further investigation. In the future, with advancements in 3D printing technology, Ecoflex is expected to achieve more precise clinical translation across multiple fields and drive innovation in intelligent biomaterials.
2.Effect of dexmedetomidine mixed with ropivacaine on postoperative sleep quality in patients undergoing upper abdominal surgery with OSTAPB
Yuefeng SUN ; Zhijie DENG ; Luheng YE ; Xinglian LI ; Su LIU ; Shanshan ZHU
The Journal of Practical Medicine 2025;41(7):1030-1035
Objective To investigate the effect of dexmedetomidine combined with ropivacaine on postop-erative sleep quality in patients undergoing upper abdominal surgery following Oblique Subcostal Transversus Abdominis Plane Block(OSTAPB).Methods A total of 140 patients who underwent gastric surgery at the Affiliated Hospital of Xuzhou Medical University between September 2024 and November 2024 were enrolled.According to the random number table method,they were randomly allocated into two groups:the simple subcostal transversus abdominis plane block group(Group A)and the dexmedetomidine combined with subcostal transversus abdominis plane block group(Group B),with 70 patients in each group.The study compared the Asymptomatic Sleep Distur-bance Scale(AIS)scores and Self-rating Anxiety Scale(SAS)scores on the night before surgery,AIS scores on the night after surgery and the following day,the amount of remifentanil used during surgery,and the cumulative num-ber of patient-controlled analgesia(PCA)button presses within 3 days postoperatively.Additionally,the Numeric Rating Scale(NRS)pain scores at 2 h,6 h,12 h,24 h,and 48 h post-surgery,as well as the Quality of Recovery-15(QoR-15)scores on the night of surgery and the second day post-surgery,were evaluated.Results There were no significant differences in anxiety levels or subjective sleep quality scores between the two groups prior to the opera-tion(P>0.05).Additionally,there was no significant difference in the usage of remifentanil between Group A and Group B(P>0.05).The NRS scores for pain differed significantly between the two groups within the first 48 hours post-operation(P<0.05);however,no significant difference was observed in NRS scores between the two groups after 24 hours during rest.Furthermore,the number of patient-controlled analgesia(PCA)activations in Group B was significantly lower than that in Group A at 12 hours post-operation(P<0.05).Lastly,both the QoR-15 and sleep quality were significantly higher in Group B compared to Group A(P<0.05).Conclusion Dexmedetomidine combined with ropivacaine for subcostal transversus abdominis plane block not only provides superior postoperative analgesia compared to ropivacaine alone but also enhances patients' sleep quality and recovery quality on the night following surgery,thereby contributing to improved overall postoperative recovery.
3.Caerulomycin A disrupts glucose metabolism and triggers ER stress-induced apoptosis in triple-negative breast cancer cells.
Ye ZHANG ; Shanshan SU ; Xiaoyu XU ; Zhixian HE ; Yiyan ZHOU ; Xiangrong LU ; Aiqin JIANG
Chinese Journal of Natural Medicines (English Ed.) 2025;23(9):1080-1091
Triple-negative breast cancer (TNBC) represents an aggressive breast cancer subtype with poor prognosis and limited targeted treatment options. This investigation examined the anti-cancer potential of Caerulomycin A (Cae A), a natural compound derived from marine actinomycetes, against TNBC. Cae A demonstrated selective inhibition of viability and proliferation in TNBC cell lines, including 4T1, MDA-MB-231, and MDA-MB-468, through apoptosis induction. Mechanistic analyses revealed that the compound induced sustained endoplasmic reticulum (ER) stress and subsequent upregulation of C/EBP homologous protein (CHOP) expression, resulting in mitochondrial damage-mediated apoptosis. Inhibition of ER stress or CHOP expression knockdown reversed mitochondrial damage and apoptosis, highlighting the essential role of ER stress and CHOP in Cae A's anti-tumor mechanism. Both oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) decreased in TNBC cells following Cae A treatment, indicating reduced mitochondrial respiratory and glycolytic capacities. This diminished energy metabolism potentially triggers ER stress and subsequent apoptosis. Furthermore, Cae A exhibited significant anti-tumor effects in the 4T1 tumor model in vivo without apparent toxicity. The compound also effectively inhibited human TNBC organoid growth. These results indicate that Cae A may serve as a potential therapeutic agent for TNBC, with its efficacy likely mediated through the disruption of glucose metabolism and the induction of ER stress-associated apoptosis.
Humans
;
Endoplasmic Reticulum Stress/drug effects*
;
Triple Negative Breast Neoplasms/genetics*
;
Apoptosis/drug effects*
;
Cell Line, Tumor
;
Female
;
Animals
;
Glucose/metabolism*
;
Mice
;
Cell Proliferation/drug effects*
;
Transcription Factor CHOP/genetics*
;
Antineoplastic Agents/pharmacology*
;
Mitochondria/metabolism*
;
Mice, Inbred BALB C
4.Multidrug resistance reversal effect of tenacissoside I through impeding EGFR methylation mediated by PRMT1 inhibition.
Donghui LIU ; Qian WANG ; Ruixue ZHANG ; Ruixin SU ; Jiaxin ZHANG ; Shanshan LIU ; Huiying LI ; Zhesheng CHEN ; Yan ZHANG ; Dexin KONG ; Yuling QIU
Chinese Journal of Natural Medicines (English Ed.) 2025;23(9):1092-1103
Cancer multidrug resistance (MDR) impairs the therapeutic efficacy of various chemotherapeutics. Novel approaches, particularly the development of MDR reversal agents, are critically needed to address this challenge. This study demonstrates that tenacissoside I (TI), a compound isolated from Marsdenia tenacissima (Roxb.) Wight et Arn, traditionally used in clinical practice as an ethnic medicine for cancer treatment, exhibits significant MDR reversal effects in ABCB1-mediated MDR cancer cells. TI reversed the resistance of SW620/AD300 and KBV200 cells to doxorubicin (DOX) and paclitaxel (PAC) by downregulating ABCB1 expression and reducing ABCB1 drug transport function. Mechanistically, protein arginine methyltransferase 1 (PRMT1), whose expression correlates with poor prognosis and shows positive association with both ABCB1 and EGFR expressions in tumor tissues, was differentially expressed in TI-treated SW620/AD300 cells. SW620/AD300 and KBV200 cells exhibited elevated levels of EGFR asymmetric dimethylarginine (aDMA) and enhanced PRMT1-EGFR interaction compared to their parental cells. Moreover, TI-induced PRMT1 downregulation impaired PRMT1-mediated aDMA of EGFR, PRMT1-EGFR interaction, and EGFR downstream signaling in SW620/AD300 and KBV200 cells. These effects were significantly reversed by PRMT1 overexpression. Additionally, TI demonstrated resistance reversal to PAC in xenograft models without detectable toxicities. This study establishes TI's MDR reversal effect in ABCB1-mediated MDR human cancer cells through inhibition of PRMT1-mediated aDMA of EGFR, suggesting TI's potential as an MDR modulator for improving chemotherapy outcomes.
Humans
;
Protein-Arginine N-Methyltransferases/antagonists & inhibitors*
;
Drug Resistance, Neoplasm/drug effects*
;
ErbB Receptors/genetics*
;
Animals
;
Cell Line, Tumor
;
Drug Resistance, Multiple/drug effects*
;
Methylation/drug effects*
;
Saponins/administration & dosage*
;
Mice
;
Mice, Nude
;
Mice, Inbred BALB C
;
ATP Binding Cassette Transporter, Subfamily B/genetics*
;
Doxorubicin/pharmacology*
;
Paclitaxel/pharmacology*
;
Female
;
Repressor Proteins
5.Multicenter study on the prediction of microvascular invasion in hepatocellular carcinoma using multiphase ultrasound imaging radiomics models
Yanhong HAO ; Juan CHEN ; Qin LU ; Ruining WANG ; Yuan SU ; Shanshan SHI ; Rui SHI ; Lingjie WANG ; Jianhong WANG ; Li YANG ; Liping LIU
Chinese Journal of Ultrasonography 2025;34(11):983-991
Objective:To construct and evaluate the predictive performance of a multiphase ultrasound radiomics model for microvascular invasion(MVI)in hepatocellular carcinoma(HCC).Methods:A total of 126 patients with pathologically confirmed HCC were retrospectively enrolled from 4 medical centers between May 2018 and July 2025,including the First Hospital of Shanxi Medical University,Shanxi Province Third People's Hospital,Changzhi People's Hospital,and the Organ Transplant Center of the Affiliated Hospital of Qingdao University. A total of 630 ultrasound images of the lesions in different phases were collected,from which 1 561 radiomic features were extracted. The patients from medical institutions in Shanxi Province were chosen as the training set( n=91),and the patients from the Organ Transplant Center of the Affiliated Hospital of Qingdao University were chosen as the validation set( n=35). In the training set,37.4%(34/91)patients presented MVI(+),whereas in the validation set,54.3%(19/35)patients presented MVI(+). Radiomics features were extracted from ultrasound images,and features related to the MVI(+)were selected through dimensionality reduction analysis. Five multiple machine learning algorithms were used to construct predictive models,which were then evaluated using an external validation set. The Radscore was calculated,and a nomogram was constructed combining Radscore with ultrasound and clinical characteristics to predict MVI. Results:The model combining radiomics features from the portal venous phase and the delay phase showed the best predictive performance in both the training and validation sets,with area under curve(AUC)values of 0.835 and 0.727,respectively. The prediction model developed using radiomics Radscore and clinical indicators could be represented and presented as a nomogram.Conclusions:The radiomics model based on multi-phase ultrasound offers a novel approach for non-invasive preoperative prediction of MVI in liver cancer. Furthermore,its integration with clinical features aids in optimizing clinical treatment strategies.
6.Effect of dexmedetomidine mixed with ropivacaine on postoperative sleep quality in patients undergoing upper abdominal surgery with OSTAPB
Yuefeng SUN ; Zhijie DENG ; Luheng YE ; Xinglian LI ; Su LIU ; Shanshan ZHU
The Journal of Practical Medicine 2025;41(7):1030-1035
Objective To investigate the effect of dexmedetomidine combined with ropivacaine on postop-erative sleep quality in patients undergoing upper abdominal surgery following Oblique Subcostal Transversus Abdominis Plane Block(OSTAPB).Methods A total of 140 patients who underwent gastric surgery at the Affiliated Hospital of Xuzhou Medical University between September 2024 and November 2024 were enrolled.According to the random number table method,they were randomly allocated into two groups:the simple subcostal transversus abdominis plane block group(Group A)and the dexmedetomidine combined with subcostal transversus abdominis plane block group(Group B),with 70 patients in each group.The study compared the Asymptomatic Sleep Distur-bance Scale(AIS)scores and Self-rating Anxiety Scale(SAS)scores on the night before surgery,AIS scores on the night after surgery and the following day,the amount of remifentanil used during surgery,and the cumulative num-ber of patient-controlled analgesia(PCA)button presses within 3 days postoperatively.Additionally,the Numeric Rating Scale(NRS)pain scores at 2 h,6 h,12 h,24 h,and 48 h post-surgery,as well as the Quality of Recovery-15(QoR-15)scores on the night of surgery and the second day post-surgery,were evaluated.Results There were no significant differences in anxiety levels or subjective sleep quality scores between the two groups prior to the opera-tion(P>0.05).Additionally,there was no significant difference in the usage of remifentanil between Group A and Group B(P>0.05).The NRS scores for pain differed significantly between the two groups within the first 48 hours post-operation(P<0.05);however,no significant difference was observed in NRS scores between the two groups after 24 hours during rest.Furthermore,the number of patient-controlled analgesia(PCA)activations in Group B was significantly lower than that in Group A at 12 hours post-operation(P<0.05).Lastly,both the QoR-15 and sleep quality were significantly higher in Group B compared to Group A(P<0.05).Conclusion Dexmedetomidine combined with ropivacaine for subcostal transversus abdominis plane block not only provides superior postoperative analgesia compared to ropivacaine alone but also enhances patients' sleep quality and recovery quality on the night following surgery,thereby contributing to improved overall postoperative recovery.
7.Protective effect and mechanism of acteoside in diabetic nephropathy
Dongyan WANG ; Zhaoan GUO ; Jingnan TANG ; Hui LIU ; Shanshan SU
Journal of China Medical University 2025;54(9):769-774,780
Objective To investigate the effects of acteoside in a rat model on of diabetic nephropathy(DN)and high-glucose-induced glomerular mesangial cells(GMCs),focusing on the role of acteoside in the silent information regulator 1(SIRT1)/nuclear factor eryth-roid 2-related factor 2(Nrf2)signaling pathway.Methods GMCs were cultured under normal glucose conditions or stimulated with high glucose.Fibrosis,oxidative stress,SIRT1 and Nrf2 protein expression,and mitochondrial structure were assessed in four groups:normal glucose,high glucose,high glucose+acteoside,and high glucose+acteoside+SIRT1 inhibitor(hsa62).DN was induced in rats via intraperitoneal streptozotocin injection,and animals were divided into control,model,and acteoside-treated groups.Pathological kidney changes,blood glucose changes,renal function indices,and protein expression of SIRT1 and Nrf2 were evaluated.Results Compared with controls,DN model rats showed significantly elevated fasting blood glucose,serum creatinine,blood urea nitrogen,and 24-h urinary protein levels of rats in the model group were significantly increased(P<0.01).GMCs exhibited increased fibrosis,oxidative stress,and mitochondrial damage.Acteoside treatment significantly improved all measured parameters(P<0.01);and mitigated mitochondrial injury.In vitro,acteoside reduced high-glucose-induced fibrosis and oxidative stress in GMCs,effects that were reversed by SIRT1 inhibition.Western blotting confirmed upregulation of SIRT1 and Nrf2 expression in both treated rat kidney tissues and GMCs(P<0.01).Conclusion Acteoside alleviates glomerular fibrosis and oxidative stress in DN by activating the SIRT1/Nrf2 signaling pathway,suggesting its potential therapeutic agent for DN.
8.Clinical efficacy and safety of a domestic calcipotriol/betamethasone dipropionate ointment in the treatment of stable plaque psoriasis: a multicenter, randomized, double-blind, controlled study
Lixin XIA ; Guang XIANG ; Qingchun DIAO ; Kun HUANG ; Shoumin ZHANG ; Shanshan LI ; Yumei LI ; Zhiqiang SONG ; Qing SUN ; Xiumin YANG ; Meng PAN ; Yuling SHI ; Shuping GUO ; Huiping WANG ; Tiechi LEI ; Xiaoyong ZHOU ; Songmei GENG ; Suchun HOU ; Juan SU ; Yong CUI ; Rixin CHEN ; Yanyan FENG ; Hongxia FENG ; Rushan XIA ; Zudong MENG ; Fang YIN ; Jingjing WANG ; Xinghua GAO
Chinese Journal of Dermatology 2025;58(11):1020-1026
Objective:To evaluate the clinical equivalence between a domestic calcipotriol/betamethasone dipropionate ointment and the originator product in the treatment of stable plaque psoriasis.Methods:A multicenter, randomized, double-blind, three-arm, parallel-group, active- and placebo-controlled study was conducted, and 449 patients aged 18 - 65 years with stable plaque psoriasis were enrolled from 25 hospitals (such as the First Affiliated Hospital of China Medical University). Eligible patients had a baseline physician's global assessment (PGA) score of ≥ 3 points, baseline body surface area (BSA) involvement of 5% - 30%, and a target lesion psoriasis area and severity index (TL-PASI) for plaque elevation of ≥ 3 points. Participants were randomly assigned in a 2:2:1 ratio to the test group ( n = 179), reference group ( n = 180), and placebo group ( n = 90), and applied the domestic calcipotriol/betamethasone dipropionate ointment, originator product, and ointment base respectively, once daily in the evening for 4 weeks. Efficacy and safety were assessed at weeks 1, 2, and 4. The primary efficacy endpoints were the treatment success rates and clinical success rates in each group at week 4. The per-protocol set (PPS) was used for the primary efficacy analysis, and the intention-to-treat (ITT) set for supplementary efficacy analysis. Equivalence between the test and reference preparations was tested using the Cochran-Mantel-Haenszel method adjusted for randomization strata. Superiority of the test and reference preparations over the placebo was also tested. Measurement data were compared among the 3 groups using analysis of variance or non-parametric tests, while treatment success rates, clinical success rates, and incidence rates of adverse reactions were compared using the chi-square test. Results:The ITT, PPS, and safety sets included 447, 420, and 448 patients, respectively. In the ITT set, patients were aged 43.6 ± 12.8 years, including 320 (71.6%) males and 127 (28.4%) females, and the disease duration was 11.21 ± 9.05 years; 316 (70.7%) had a PGA score of 3 points and 131 (29.3%) had a PGA score of 4 - 5 points. No significant differences in the baseline characteristics (including age, sex, disease duration and disease severity) were observed among the 3 groups (all P > 0.05). Based on the PPS analysis, the treatment success rates were 57.9% (99/171) in the test group, 50.3% (86/171) in the reference group, and 7.7% (6/78) in the placebo group, and the clinical success rates were 57.9% (99/171), 50.3% (86/171), and 10.3% (8/78), respectively; both the test and reference groups were superior to the placebo group in both treatment and clinical success rates (all P < 0.001) ; the rate differences for treatment success (90% confidence interval [ CI]: -1.3% - 16.4%) and clinical success (90% CI: -1.3% - 16.3%) between the test and reference groups were entirely within the pre-defined equivalence margin (-20% - 20%). Subgroup analyses by baseline PGA scores: for patients with a baseline PGA score of 3 points, the treatment success rates in the test, reference, and placebo groups were 60.8% (73/120), 52.1% (62/119), and 11.1% (6/54), respectively, and the corresponding clinical success rates were 61.7% (74/120), 53.8% (64/119), and 13% (7/54), respectively; the test and reference groups did not differ significantly in treatment or clinical success rates (both P > 0.05), but both showed higher success rates than the placebo group (all P < 0.001) ; the results of statistical comparisons among the 3 groups in patients with a baseline PGA score of 4 - 5 points were consistent with those observed in patients with a baseline PGA score of 3 points. The percentage reductions in PGA and TL-PASI scores from baseline to weeks 1, 2, and 4 showed significant differences among the 3 groups, which were significantly higher in the test and reference groups than in the placebo group (all P < 0.001), but did not differ between the test and reference groups (all P > 0.05). The primary adverse reactions were local skin reactions, such as pruritus, pain, and erythema. The incidence rates of adverse reactions were 8.9% (16/179) in the test group, 7.3% (13/179) in the reference group, and 7.8% (7/90) in the placebo group, with no significant difference among the 3 groups ( P > 0.05) . Conclusions:The domestic calcipotriol/betamethasone dipropionate ointment demonstrated clinical equivalence to the originator product in the treatment of stable plaque psoriasis, and the two agents exhibited comparable efficacy for patients with varying degrees of disease severity, and were comparable in the speed and degree of clinical improvement, with similar favorable safety profiles.
9.Investigation on knowledge related to tuberculin skin test among 248 healthcare workers
Wen ZHANG ; Yaling SHI ; Shanshan LIU ; Qian SU ; Yu XIN ; Liyi ZHANG ; Juan LYU ; Wenping LIAO ; Jun FAN
Chongqing Medicine 2025;54(3):709-712,718
Objective To investigate the knowledge of tuberculin skin test(TST)among healthcare workers and provide evidence for improving the standardization of TST screening in primary healthcare staff.Methods A questionnaire survey was conducted among 248 licensed physicians or nurses who were qualified as licensed physicians or nurses and responsible for TST work from 27 districts/counties of Chongqing in 2023.The awareness of TST-related knowledge and its influencing factors were statistically analyzed.Results The average TST knowledge score of 248 healthcare workers was(78.3±10.6)points.The overall awareness rate was 78.9%(8 213/10 416),with specific rates as follows:65.4%(1 135/1 736)for tubercu-losis knowledge,87.3%(3 248/3 720)for TST general knowledge,53.4%(795/1 488)for TST principles,88.0%(1 964/2 232)for TST procedures,and 86.4%(1 071/1 240)for TST result interpretation.Nurses showed higher awareness rates than physicians and other staff(P>0.05).Healthcare workers from medium-epidemic areas demonstrated significantly higher awareness rates than those from high-and low-epidemic are-as(P<0.001).No statistically significant differences were observed in gender,age,occupation type,institu-tion type,or regional epidemic level between the qualified group and non-qualified group about TST-related knowl-edge(P>0.05).Conclusion Healthcare workers exhibit incomplete mastery of TST-related knowledge.Strengthening TST-related knowledge training for standardizing TST implementation.
10.Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.
Jingyi LI ; Yunsheng LIANG ; Wenli FENG ; Liehua DENG ; Hong FANG ; Chao JI ; Youkun LIN ; Furen ZHANG ; Rushan XIA ; Chunlei ZHANG ; Shuping GUO ; Mao LIN ; Yanling LI ; Shoumin ZHANG ; Xiaojing KANG ; Liuqing CHEN ; Zhiqiang SONG ; Xu YAO ; Chengxin LI ; Xiuping HAN ; Guoxiang GUO ; Qing GUO ; Xinsuo DUAN ; Jie LI ; Juan SU ; Shanshan LI ; Qing SUN ; Juan TAO ; Yangfeng DING ; Danqi DENG ; Fuqiu LI ; Haiyun SUO ; Shunquan WU ; Jingbo QIU ; Hongmei LUO ; Linfeng LI ; Ruoyu LI
Chinese Medical Journal 2025;138(16):2040-2042


Result Analysis
Print
Save
E-mail